KR20050054696A - Basidiomycetes-fermented cereal effective in adjusting blood sugar level - Google Patents
Basidiomycetes-fermented cereal effective in adjusting blood sugar level Download PDFInfo
- Publication number
- KR20050054696A KR20050054696A KR1020030088211A KR20030088211A KR20050054696A KR 20050054696 A KR20050054696 A KR 20050054696A KR 1020030088211 A KR1020030088211 A KR 1020030088211A KR 20030088211 A KR20030088211 A KR 20030088211A KR 20050054696 A KR20050054696 A KR 20050054696A
- Authority
- KR
- South Korea
- Prior art keywords
- mushroom
- grains
- mushroom culture
- glucose
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 235000013339 cereals Nutrition 0.000 title claims description 52
- 239000008280 blood Substances 0.000 title abstract description 24
- 210000004369 blood Anatomy 0.000 title abstract description 24
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 110
- 244000184734 Pyrus japonica Species 0.000 claims abstract description 31
- 241001236817 Paecilomyces <Clavicipitaceae> Species 0.000 claims abstract description 14
- 235000013305 food Nutrition 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 240000005979 Hordeum vulgare Species 0.000 claims description 13
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 13
- 235000021329 brown rice Nutrition 0.000 claims description 13
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 51
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 44
- 239000008103 glucose Substances 0.000 abstract description 44
- 230000001747 exhibiting effect Effects 0.000 abstract description 13
- 230000002641 glycemic effect Effects 0.000 abstract description 13
- 238000012258 culturing Methods 0.000 abstract description 5
- 235000013376 functional food Nutrition 0.000 abstract description 3
- 230000010030 glucose lowering effect Effects 0.000 abstract description 2
- 230000004941 influx Effects 0.000 abstract description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 18
- 108010028144 alpha-Glucosidases Proteins 0.000 description 18
- 239000000284 extract Substances 0.000 description 16
- 230000002401 inhibitory effect Effects 0.000 description 15
- 206010012601 diabetes mellitus Diseases 0.000 description 13
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 9
- 241000001727 Tropicoporus linteus Species 0.000 description 9
- 244000046052 Phaseolus vulgaris Species 0.000 description 7
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 7
- 235000007685 Pleurotus columbinus Nutrition 0.000 description 7
- 240000001462 Pleurotus ostreatus Species 0.000 description 7
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 241001327634 Agaricus blazei Species 0.000 description 6
- 241001264174 Cordyceps militaris Species 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 240000001417 Vigna umbellata Species 0.000 description 6
- 235000011453 Vigna umbellata Nutrition 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 240000008397 Ganoderma lucidum Species 0.000 description 5
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 5
- 240000000599 Lentinula edodes Species 0.000 description 5
- 235000001715 Lentinula edodes Nutrition 0.000 description 5
- 241001282857 Mycoacia fuscoatra Species 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000001814 pectin Substances 0.000 description 5
- 229920001277 pectin Polymers 0.000 description 5
- 235000010987 pectin Nutrition 0.000 description 5
- 244000070268 Agaricus arvensis Species 0.000 description 4
- 235000008318 Agaricus arvensis Nutrition 0.000 description 4
- 241000222356 Coriolus Species 0.000 description 4
- 241000504964 Echinoderma asperum Species 0.000 description 4
- 240000006499 Flammulina velutipes Species 0.000 description 4
- 235000016640 Flammulina velutipes Nutrition 0.000 description 4
- 241000123330 Fomes fomentarius Species 0.000 description 4
- 241001051240 Gloeophyllum abietinum Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 4
- 241001635641 Oxyporus <beetle> Species 0.000 description 4
- 241001278897 Porodaedalea chrysoloma Species 0.000 description 4
- 241001476306 Stereum gausapatum Species 0.000 description 4
- 241001236266 Tolypocladium ophioglossoides Species 0.000 description 4
- 241000222355 Trametes versicolor Species 0.000 description 4
- 241001619444 Wolfiporia cocos Species 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- 241000567030 Ampulloclitocybe clavipes Species 0.000 description 3
- 244000275339 Clavicorona pyxidata Species 0.000 description 3
- 235000016842 Clavicorona pyxidata Nutrition 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 240000005995 Laetiporus sulphureus Species 0.000 description 3
- 235000007714 Laetiporus sulphureus Nutrition 0.000 description 3
- 241000222635 Lenzites betulinus Species 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 3
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 3
- 241000123255 Peniophora Species 0.000 description 3
- 241000222397 Phlebia radiata Species 0.000 description 3
- 241000410088 Phlebia tremellosa Species 0.000 description 3
- 241000222645 Trametes cinnabarina Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 2
- 241001149422 Ganoderma applanatum Species 0.000 description 2
- 241001489158 Ganoderma valesiacum Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 241000123107 Phellinus Species 0.000 description 2
- 241000123113 Phellinus igniarius Species 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 241001619454 Wolfiporia Species 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 4-nitrophenyl alpha-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000222518 Agaricus Species 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000222689 Laetiporus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 241001556385 Sanghuangporus baumii Species 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 파에실로마이세스 자포니카(Paecilomyces japonica)를 곡물에 배양하여 제조되고, 혈당조절효과를 나타내는 버섯배양곡물, 전기 버섯배양곡물을 제조하는 방법 및 전기 버섯배양곡물을 주재로 포함하고, 혈당저하 효과를 나타내는 식품에 관한 것이다. 본 발명의 버섯배양곡물은 포도당의 생성을 저해하고, 생성된 포도당의 체내 유입을 저하시키므로, 혈당조절효과를 나타내는 기능성 식품의 개발에 널리 활용될 수 있을 것이다.The present invention is prepared by culturing Paecilomyces japonica (Pecilomyces japonica) in grains, comprising a mushroom culture grains, a method for producing an electric mushroom culture grains and an electric mushroom culture grains exhibiting a glycemic control effect, blood glucose lowering It relates to a food product having an effect. Mushroom culture grains of the present invention inhibits the production of glucose, and lowers the influx of the generated glucose in the body, it can be widely used in the development of functional foods exhibiting a glycemic control effect.
Description
본 발명은 혈당조절효과를 나타내는 버섯배양곡물에 관한 것이다, 좀 더 구체적으로, 본 발명은 파에실로마이세스 자포니카(Paecilomyces japonica)를 곡물에 배양하여 제조되어, 혈당조절효과를 나타내는 버섯배양곡물, 전기 버섯배양곡물을 제조하는 방법 및 전기 버섯배양곡물을 주재로 포함하고, 혈당저하 효과를 나타내는 식품에 관한 것이다.The present invention relates to a mushroom culture grain exhibiting a glycemic control effect, more specifically, the present invention is prepared by culturing Paecilomyces japonica in grains, mushroom culture grains exhibiting a glycemic control effect, electric The present invention relates to a method for producing a mushroom culture grain, and a food containing an electric mushroom culture grain as a main agent and exhibiting a hypoglycemic effect.
현대의학으로 당뇨병을 근원적으로 치료할 수 있는 방법은 아직 개발되지 않은 실정이며, 혈당을 정상적인 수준으로 유지되도록 하는 것이 최선의 치료방법으로 알려져 있다(참조: Strowig, S. and Raskin, P., Diabetes Care, 15:1126, 1992).Modern medicine has not yet been developed to treat diabetes, and it is known that the best treatment is to keep blood sugar at a normal level (see Strowig, S. and Raskin, P., Diabetes Care). , 15: 1126, 1992).
현재, 당뇨병의 치료방법으로는 식이요법, 운동요법과 함께 약물요법이 시도되고 있고 임상에서 사용되고 있는 약물로는 인슐린 제제, sulfonylurea 제제, biguanide 제제, troglitazone 제제 등이 있다. 경구용 혈당강하제로 주로 쓰이는 sulfonylurea 제제는 장기적으로 사용할 때 β-세포의 탈진을 일으킬 수 있고 부작용으로 저혈당의 위험이 따르며, biguanide계의 metformin도 우수한 약제이지만 간혹 유산증이라는 치명적인 부작용을 가져올 수 있다(참조: Groop, L.C., Diebetes Care, 15:737-754, 1992). 또한 인슐린 주사요법은 환자에게 불편할 뿐 아니라 저혈당의 위험성이 따르고 장기 사용시 비만을 촉진시켜 인슐린 비의존형 당뇨병 환자의 경우 장기적인 혈당 관리에 어려움을 줄 수 있다(참조: Koivisto, V.A., Diabetes Care, 16:29-39, 1993). Currently, as a treatment method for diabetes, drug therapy is being attempted along with diet and exercise therapy, and drugs used in clinical practice include insulin preparation, sulfonylurea preparation, biguanide preparation, and troglitazone preparation. The sulfonylurea preparation, which is mainly used as an oral hypoglycemic agent, may cause β-cell exhaustion in the long term, and the risk of hypoglycemia as a side effect, and the biguanide metformin is also an excellent drug, but sometimes it may cause fatal side effects such as lactic acid. Groop, LC, Diebetes Care, 15: 737-754, 1992). In addition, insulin injection therapy is not only inconvenient for patients, but also has a low risk of hypoglycemia and promotes obesity in long-term use, which may cause difficulty in managing long-term blood glucose levels in patients with insulin-independent diabetes (see Koivisto, VA, Diabetes Care, 16:29). -39, 1993).
최근에는, 부작용이 우려되는 약물치료 이외에 민간요법이나 자연식품 등을 통해 혈당을 정상상태로 유지하고자 하는 경향이 두드러져 천연물 및 식품원료로부터 혈당강하 소재를 개발하고자 하는 연구가 활발히 진행되고 있다. 민간요법에서 효능이 있는 것으로 알려져 많이 이용되어 오던 작물인 닭의장풀 추출액, 두릅나무와 현삼이 정상 또는 고혈당이 유발된 마우스에서 혈당강하작용이 있음이 확인되었고, 갈근의 물추출물, 음양곽 추출물, 달개비풀 등도 효과가 확인된 바 있다(참조: Kim, O.K., Kor. J. Pharmacogn., 22:225-232, 1991; Kim, O.K., Kor. J. Pharmacogn., 23:117-119, 1992; Kim, J.Y., J. K. Diabetes Assoc., 18:377-381, 1994).Recently, there is a tendency to maintain blood sugar in a normal state through folk remedies or natural foods, in addition to drug treatments that are concerned about side effects, and researches to develop blood glucose lowering materials from natural products and food ingredients have been actively conducted. It has been confirmed that the extracts of chicken berry grass, arborella and Hyunsam, which have been widely used in folk medicine, have a hypoglycemic effect in normal or hyperglycemic-induced mice. Effects have been identified (Kim, OK, Kor. J. Pharmacogn., 22: 225-232, 1991; Kim, OK, Kor. J. Pharmacogn., 23: 117-119, 1992; Kim, JY , JK Diabetes Assoc., 18: 377-381, 1994).
고등균류 중 버섯자원은 8,000여종으로 그 중에서 20여종은 옛부터 식용과 약용으로 활용되어 왔으며 최근에는 전 세계적으로 버섯균의 생리활성 물질이나 기능성 성분에 대한 연구가 활발히 진행되어 항암성, 면역활성증강, 혈압강하, 혈전용해, 혈중 콜레스테롤 저하작용 등이 과학적으로 입증되었고, 일부 약용 버섯류에 포함된 성분이 혈당강하 효과를 나타낼 수도 있다고 보고되어, 당뇨병 치료를 위하여 버섯을 연구하려는 노력이 계속되고 있다(참조: Lucas, E.H. and Ringler, R.L., Antibiotics and Chemotheraphy, 7:1-4, 1957; Chihara, G. et al., Cancer Res., 30:2776-2781, 1970; Nagata, J. et al., J. Agric. Food Chem., 49:4965-4970, 2001; Zhuang, C. et al., J. Jpn. Soc. Food Sci. Technol., 41:724-732, 1994; Watanabe, T. et al., J. Jap. Soc. Food Sci. Technol., 49:166-173, 2002; Sumi, H. et al., J. Jpn. Soc. Food Sci. Technol., 43:318-321, 1996; Cheung, P.C.K., Nutr. Res., 16:1953-1957, 1996; Sugiyama, K. et al., J. Jap. Soc. Nutr. Food Sci., 45:265-270, 1992; Kurasawa, S.I. et al., Nutr. Reports International, 26:167-173, 1982; Ukawa, Y. et al., J. Nutr. Sci. Vit., 48:73-76, 2002; Yuan, Z. et al., Biosci. Biotechnol. Biochem., 62:1898-1903, 1998; Kiho, T. et al., Carbohydr. Res., 251:81-87, 1994).More than 8,000 mushroom resources are among the higher fungi, and 20 of them have been used for food and medicinal use since ancient times. Recently, researches on bioactive substances and functional ingredients of mushrooms have been actively conducted worldwide. , Blood pressure lowering, thrombolysis, and blood cholesterol lowering have been scientifically proven, and some medicinal mushrooms have been reported to have hypoglycemic effects, and efforts are being made to study mushrooms for the treatment of diabetes. See: Lucas, EH and Ringler, RL, Antibiotics and Chemotheraphy, 7: 1-4, 1957; Chihara, G. et al., Cancer Res., 30: 2776-2781, 1970; Nagata, J. et al., J. Agric. Food Chem., 49: 4965-4970, 2001; Zhuang, C. et al., J. Jpn. Soc. Food Sci.Technol., 41: 724-732, 1994; Watanabe, T. et al. ., J. Jap. Soc. Food Sci. Technol., 49: 166-173, 2002; Sumi, H. et al., J. Jpn. Soc. Food Sci.Technol., 43: 318-321, 19. 96; Cheung, PCK, Nutr.Res., 16: 1953-1957, 1996; Sugiyama, K. et al., J. Jap.Soc.Nutr.Food Sci., 45: 265-270, 1992; Kurasawa, SI et al., Nutr. Reports International, 26: 167-173, 1982; Ukawa, Y. et al., J. Nutr. Sci. Vit., 48: 73-76, 2002; Yuan, Z. et al., Biosci. Biotechnol. Biochem., 62: 1898-1903, 1998; Kiho, T. et al., Carbohydr.Res., 251: 81-87, 1994).
그러나, 현재까지는 직접적으로 버섯을 당뇨병치료에 사용하지 못하고 있는데, 이는 약용 버섯의 상식이 용이하지 않고, 혈당강하 효과를 나타내는 유효성분이 약용버섯에 극히 미량으로 존재하며, 약용버섯을 재배하기 위하여 장기간의 시간이 소요되기 때문이다. 그러나, 버섯을 당뇨병 치료에 효과적으로 이용할 수 있다면, 별도의 치료제를 투여하지 않고, 식이요법으로 당뇨병을 치료할 수 있을 것으로 예상되어, 이에 대한 연구가 가속화되고 있으나, 아직까지는 별다른 진전이 없는 실정이다.However, until now, mushrooms have not been directly used for the treatment of diabetes mellitus, which is not easy for common sense of medicinal mushrooms, and there are very small amounts of active ingredients that have a hypoglycemic effect in medicinal mushrooms, It takes time. However, if the mushroom can be effectively used for the treatment of diabetes, it is expected to be able to treat diabetes by diet without administering a separate therapeutic agent, and research on this is being accelerated, but there is no progress yet.
따라서, 버섯을 이용하여 당뇨병을 치료할 수 있는 방법을 개발하여야 할 필요성이 끊임없이 대두되었다.Therefore, there is a constant need to develop a method for treating diabetes using mushrooms.
이에, 본 발명자는 버섯을 이용하여 당뇨병을 치료할 수 있는 방법을 개발하고자 예의 연구노력한 결과, 버섯을 곡물에 접종시킨 후, 배양하는 고체배양 방법을 이용하여 제조된, 버섯배양곡물이 혈당을 현저히 낮출 수 있음을 확인하고, 본 발명을 완성하게 되었다. Accordingly, the present inventors have made intensive studies to develop a method for treating diabetes by using mushrooms. As a result of inoculating mushrooms into grains, mushroom culture grains prepared by using a solid culture method of cultivating significantly lower blood sugar. It was confirmed that the present invention can be completed.
결국, 본 발명의 주된 목적은 혈당저하 효과를 나타내는 버섯배양곡물을 제공하는 것이다.After all, the main object of the present invention is to provide a mushroom culture grain exhibiting a hypoglycemic effect.
본 발명의 다른 목적은 전기 버섯배양곡물의 제조방법을 제공하는 것이다.Another object of the present invention is to provide a method for producing an electric mushroom culture grain.
본 발명의 또 다른 목적은 전기 버섯배양곡물을 주재로 포함하고, 혈당조절 효과를 나타내는 식품을 제공하는 것이다. Still another object of the present invention is to provide a food containing an electric mushroom culture grain as a main ingredient and exhibiting a glycemic control effect.
본 발명의 혈당조절효과를 나타내는 버섯배양곡물의 제조방법은 곡물을 수침시키고, 살균하는 공정; 및, 전기 살균된 곡물에 파에실로마이세스 자포니카(Paecilomyces japonica, KCTC 9817)를 접종하고 배양하여, 버섯배양곡물을 수득하는 공정을 포함한다: 이때, 곡물이 특별히 이에 제한되지는 않으나, 현미, 보리, 율무 등을 사용함이 바람직하고, 살균하는 방법이 특별히 이에 제한되는 것은 아니나, 고온살균, 고온고압살균 등의 방법을 사용함이 바람직하며, 파에실로마이세스 자포니카를 배양하는 조건이 특별히 이에 제한되는 것은 아니나, 통상적인 버섯의 재배방법과 같이 20 내지 30℃에서, 2 내지 4주간 배양함이 바람직하다.Method for producing a mushroom culture grains exhibiting a glycemic control effect of the present invention is a step of immersing and sterilizing grains; And inoculating and incubating Paecilomyces japonica (KCTC 9817) on the electrosterilized grains to obtain mushroom culture grains, wherein the grains are not particularly limited, but brown rice, barley It is preferable to use Yulmu, and the like, and the method of sterilization is not particularly limited thereto, but it is preferable to use methods such as high temperature sterilization and high pressure autoclaving, and conditions for culturing Paesilomyses japonica are particularly limited thereto. However, it is preferable to incubate for 2 to 4 weeks at 20 to 30 ℃ as in the conventional mushroom cultivation method.
우선, 본 발명자들은 혈당조절효과를 나타내는 버섯을 검색하기 위하여, 공지된 약용버섯인 아가리쿠스 버섯(Agaricus arvensis, Agaricus blazei), 동충하초(Cordyceps militaris, Cordyceps ophioglossoides, Cordyceps sinensis, Paecilomyces japonica), 영지버섯(Ganoderma applanatum, Ganoderma lucidum, Ganoderma valesiacum), 진흙버섯(Phellinus baumi, Phellinus chrysoloma, Phellinus igniarius, Phellinus japonica, Phellinus linteus) 및 복령(Wolfiporia cocos, Wolfiporia extensa)과 그 외의 버섯(Coriolus azureus, Stereum gausapatum, Gloeophyllum abietinum, Grifora frondosa, Laetiporus sulphureus, Lentinus edodes, Lenzites betulina, Merulius tremellosus, Mycoacia fuscoatra, Oxyporus latemarginata, Amanita aspera, Clavicorona pyxidata, Clitocybe clavipes, Peniophora quercina, Phlebia radiata, Pleurotus ostreatus, Pycnoporus cinnabarinus, Trametes versicolor, Flammulina velutipes, Fomes fomentarius)을 대상으로 하여, 균사추출물을 수득하고, 수득한 추출물의 α-글루코시다제(α-glucosidase)의 활성억제 효과, 포도당 투과억제 효과 및 당부하 정도를 측정한 결과, 동충하초에 속하는 파에실로마이세스 자포니카(Paecilomyces japonica)가 가장 우수함을 알 수 있었다.First, the inventors of the present invention, in order to search for a mushroom that exhibits a glycemic control effect, known medicinal mushroom Agaricus mushroom (Agaricus arvensis, Agaricus blazei), Cordyceps sinensis (Cordyceps militaris, Cordyceps ophioglossoides, Cordyceps sinensis, Paecilomyces japonica), Ganoderma lucidum mushroom (Ganoderma applanatum, Ganoderma lucidum, Ganoderma valesiacum), Mud Mushrooms (Phellinus baumi, Phellinus chrysoloma, Phellinus igniarius, Phellinus japonica, Phellinus linteus) And Refuge (Wolfiporia cocos, Wolfiporia extensa) And other mushrooms (Coriolus azureus, Stereum gausapatum, Gloeophyllum abietinum, Grifora frondosa, Laetiporus sulphureus, Lentinus edodes, Lenzites betulina, Merulius tremellosus, Mycoacia fuscoatra, Oxyporus latemarginata, Amanita aspera cla, Clacetusadinocabe , Trametes versicolor, Flammulina velutipes, Fomes fomentarius), The mycelia extracts were obtained, and the activity inhibitory effect, α-glucosidase inhibitory effect, glucose permeation inhibitory effect, and glucose load degree of α-glucosidase of the obtained extract were measured. Paesilomyses Japonica (Paecilomyces japonica) Was the best.
또한, 전기 선별된 균주를 현미, 보리 등에 접종하고 배양하여 제조된 파에실로마이세스 자포니카배양 곡물이 α-글루코시다제의 활성을 효과적으로 억제함을 알 수 있었다. 상기 결과를 확인하기 위하여, 실험실환경(in vitro)에서의 포도당 투과지연효과 및 체내환경(in vivo)에서의 당부하효과를 측정한 결과, 파에실로마이세스 자포니카를 현미와 보리에 배양한 버섯배양현미 및 버섯배양보리가 우수한 혈당조절 효과를 나타냄을 알 수 있었다.In addition, it can be seen that the Paesylomyces japonica culture grains prepared by inoculating the strains previously selected and cultured with brown rice and barley effectively inhibit the activity of α-glucosidase. In order to confirm the above results, mushroom cultures in which Paesilomyces japonica was cultured in brown rice and barley as a result of measuring glucose permeation delay effect in laboratory environment and glucose loading effect in in vivo environment Brown rice and mushroom cultured barley showed an excellent glycemic control effect.
이에 따라, 본 발명의 버섯배양곡물은 그 자체를 섭식하여, 혈당을 조절하는데 사용할 수도 있을 뿐만 아니라, 본 발명의 버섯배양곡물을 주재로 하여 식품을 제조할 경우, 제조된 식품은 혈당조절효과를 나타낼 수 있을 것으로 예축되므로, 본 발명의 버섯배양곡물은 혈당조절효과를 나타내는 기능성 식품의 개발에 널리 활용될 수도 있을 것이다.Accordingly, the mushroom culture grains of the present invention can be used to control blood sugar by feeding on itself, and when the food is produced based on the mushroom culture grains of the present invention, the prepared food has a glycemic control effect. Because it is expected to be represented, the mushroom culture grains of the present invention may be widely used in the development of functional foods exhibiting a glycemic control effect.
이하, 실시예를 통하여 본 발명을 보다 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention in more detail, it will be apparent to those of ordinary skill in the art that the scope of the present invention is not limited by these examples in accordance with the gist of the present invention. .
실시예 1: 버섯의 α-글루코시다제의 활성억제효과 Example 1 Activity Inhibition Effect of α-Glucosidase of Mushrooms
다양한 버섯을 배양하고, 이로부터 균사추출물을 수득한 다음, 수득한 균사추출물의 α-글루코시다제의 활성억제정도를 측정하였다.Various mushrooms were cultivated, mycelia extracts were obtained therefrom, and the degree of activity inhibition of α-glucosidase of the obtained mycelia extracts was measured.
실시예 1-1: 버섯 균사추출물의 수득 Example 1-1 : Mushroom Mycelia Extract
공지된 약용버섯인 아가리쿠스 버섯(Agaricus arvensis, Agaricus blazei), 동충하초(Cordyceps militaris, Cordyceps ophioglossoides, Cordyceps sinensis, Paecilomyces japonica), 영지버섯(Ganoderma applanatum, Ganoderma lucidum, Ganoderma valesiacum), 진흙버섯(Phellinus baumi, Phellinus chrysoloma, Phellinus igniarius, Phellinus japonica, Phellinus linteus) 및 복령(Wolfiporia cocos, Wolfiporia extensa)과 그 외의 버섯(Coriolus azureus, Stereum gausapatum, Gloeophyllum abietinum, Grifora frondosa, Laetiporus sulphureus, Lentinus edodes, Lenzites betulina, Merulius tremellosus, Mycoacia fuscoatra, Oxyporus latemarginata, Amanita aspera, Clavicorona pyxidata, Clitocybe clavipes, Peniophora quercina, Phlebia radiata, Pleurotus ostreatus, Pycnoporus cinnabarinus, Trametes versicolor, Flammulina velutipes, Fomes fomentarius)을 각각, 한천 평판배지 상에서 일정시간 배양하고, 1cm2의 크기로 절편을 수득하여, 회전 진탕 배양기에서 100rpm으로 암조건 하에서 4주동안 배양하였다. 균사체가 충분히 성장한 후, 감압여과하여 균사체와 배양액을 분리하여 균사체를 수득하고, 이를 동결건조한 다음 75%(v/v) 메탄올 수용액으로 85℃의 온도에서 3시간씩 2회 반복 추출하여, 균사추출물을 수득하고, 10mg/ml의 농도로 DMSO에 용해시켜서 시료로 사용하였다. 이때, 각 버섯의 배양조건은 표 1과 같다.Known medicinal mushrooms Agaricus arvensis, Agaricus blazei , Cordyceps militaris, Cordyceps ophioglossoides, Cordyceps sinensis, Paecilomyces japonica , Ganoderma applanatum, Ganoderma lucidum, Ganoderma valesiacum Phellinus chrysoloma, Phellinus igniarius, Phellinus japonica, Phellinus linteus ) and Bokyeong ( Wolfiporia cocos, Wolfiporia extensa ) and other mushrooms ( Coriolus azureus, Stereum gausapatum, Gloeophyllum abietinum, Grifora frondosa, Laetiporus Lentinulius benzustensulus phus) fuscoatra, the Oxyporus latemarginata, Amanita aspera, Clavicorona pyxidata, Clitocybe clavipes, Peniophora quercina, Phlebia radiata, Pleurotus ostreatus, Pycnoporus cinnabarinus, Trametes versicolor, Flammulina velutipes, Fomes fomentarius), respectively, a certain amount of time the culture, and 1cm 2 on the agar plate medium Obtain slices by size, rotating shake vessel Incubated for 4 weeks under dark conditions at 100 rpm in both phases. After the mycelium is sufficiently grown, the mycelium is cultured under reduced pressure to obtain the mycelium. The mycelium is lyophilized, and the mycelium extract is repeatedly extracted twice at a temperature of 85 ° C. with 75% (v / v) aqueous methanol solution for 3 hours. Was obtained, dissolved in DMSO at a concentration of 10 mg / ml, and used as a sample. At this time, the culture conditions of each mushroom are shown in Table 1.
실시예 1-2: α-글루코시다제의 활성억제효과 측정 Example 1-2 : Activity Inhibition Effect of α-Glucosidase
균사체 추출물의 α-글루코시다제에 대한 저해활성은 p-니트로페닐 α-D-글루코피라노시드(p-nitrophenyl α-D-glucopyranoside, 6mM), α-글루코시다제(1.4mU/mL) 및 균사체 추출물(1.0mg/mL)을 혼합하여 37℃에서 30분간 반응시킨 후, 0.4M 글리신 완충용액(glycine buffer, pH 10.4)를 가하고, 원심분리하여 수득한 상층액을 대상으로 400nm에서의 흡광도를 측정하여, 반응시간 동안의 흡광도의 변화를 DMSO를 첨가한 대조군의 흡광도의 변화의 비로부터 계산하였다(참조: 표 2). 이때. 대조군으로는 α-글루코시다제 저해제인 아카보스(acarbose)를 사용하였다.Inhibitory activity of the mycelium extract on α-glucosidase was p-nitrophenyl α-D-glucopyranoside (6 mM), α-glucosidase (1.4 mM / mL) and After mixing mycelial extract (1.0mg / mL) and reacting at 37 ° C for 30 minutes, 0.4M glycine buffer (pH 10.4) was added, and the absorbance at 400 nm was measured for the supernatant obtained by centrifugation. By measuring, the change in absorbance during the reaction time was calculated from the ratio of the change in absorbance of the control group with DMSO (see Table 2). At this time. As a control, acarbose (acarbose) was used as an α-glucosidase inhibitor.
상기 표 2에서 보듯이, 몇 종류의 버섯에서 α-글루코시다제의 활성을 억제하는 활성이 나타남을 알 수 있었으므로, 양호한 α-글루코시다제의 활성억제 효과를 나타내는 10종의 버섯(Agaricus blazei, Cordyceps militaris, Cordyceps sinensis, Paecilomyces japonica, Ganoderma lucidum, Phellinus chrysoloma, Phellinus linteus, Lentinus edodes, Mycoacia fuscoatra, Pleurotus ostreatus)을 선별하였다.As shown in Table 2, it was found that the activity of inhibiting the activity of α-glucosidase in several kinds of mushrooms, 10 kinds of mushrooms ( Agaricus blazei) exhibiting good activity inhibitory effect of α-glucosidase , Cordyceps militaris, Cordyceps sinensis, Paecilomyces japonica, Ganoderma lucidum, Phellinus chrysoloma, Phellinus linteus, Lentinus edodes, Mycoacia fuscoatra, Pleurotus ostreatus ).
실시예 1-3: 포도당 투과지연 효과 Example 1-3 Glucose Permeation Delay Effect
전기 실시예 1-2의 결과에서 양호한 효과를 나타내는 버섯을 대상으로 하여 실험실적 조건(in vitro)에서 포도당 투과지연 효과를 측정하였다. 이를 위하여, 투석막에 포도당 수용액을 넣고 투석한 후, 투석막 내부에 잔류하는 포도당의 양을 측정하여, 잔류하는 포도당이 많을수록, 포도당의 투과가 지연되는 것으로 간주하며, 이 경우에는 체내에서도 포도당의 흡수가 저해된다고 유추할 수 있다.The glucose permeation delay effect was measured under the experimental conditions (in vitro), targeting the mushrooms showing a good effect in the results of Example 1-2. For this purpose, after the dialysis membrane is put in aqueous solution of dialysis, the amount of glucose remaining in the dialysis membrane is measured, and the more glucose remaining, the glucose permeation is considered to be delayed. In this case, the absorption of glucose in the body It can be inferred that it is inhibited.
즉, 투석막(dialysis membrane, MWCO 6000~8000, Spectrum Medical Industries, Inc., USA) 내에, 실시예 1-2에서 양호한 효과를 나타낸 버섯 균사체 추출물 300ppm 과 1%(w/v) 농도의 포도당을 용해시킨 혼합용액 10mL를 넣은 다음, 이를 500mL 용량의 비이커에 담고 25℃에서 100rpm의 속도로 진탕하면서 일정시간 간격(0, 30 또는 120분)으로 투석막 외액에서 0.1mL 씩을 취하여 포도당 농도를 측정하였으며, 이를 투석막 내액에 잔존하는 포도당의 양으로 환산하였다(참조: 표 3). 이때, 포도당의 농도는 포도당 분석키트(Megazyme Pty, Ltd., Ireland)를 사용하여 측정하고, 대조군으로는 펙틴(pectin, Sigma Chemical Co., USA)을 동일 농도로 사용하였다. In other words, 300 ppm and 1% (w / v) glucose of mushroom mycelium extract exhibiting good effects in Example 1-2 were dissolved in a dialysis membrane (MWCO 6000-8000, Spectrum Medical Industries, Inc., USA). 10 mL of the mixed solution was added and placed in a 500 mL beaker and shaken at 25 rpm at 100 rpm for 0.1 mL of the dialysis membrane external solution at regular intervals (0, 30 or 120 minutes) to measure glucose concentration. It was converted into the amount of glucose remaining in the dialysis membrane solution (see Table 3). At this time, the concentration of glucose was measured using a glucose analysis kit (Megazyme Pty, Ltd., Ireland), and as a control, pectin (pectin, Sigma Chemical Co., USA) was used at the same concentration.
상기 표 3에서 보듯이, 대부분의 버섯균사체 추출물이 대조군에 비하여 포도당의 투과를 지연시키는 효과를 나타내었으나, 지연 정도에 차이가 있었으며, 진흙버섯(Phellinus linteus)이 가장 높은 투과지연 효과를 나타내었다. 이에, 120분 경과 후에 25% 이상의 농도로 포도당 투과지연 효과를 나타내는 4종의 버섯(Cordyceps sinensis, Paecilomyces japonica, Phellinus linteus, Pleurotus ostreatus)을 선별하였다.As shown in Table 3, the extract of most mushroom mycelium showed the effect of delaying the permeation of glucose compared to the control group, there was a difference in the degree of delay, mud mushroom ( Phellinus linteus ) showed the highest permeation delay effect. Therefore, four kinds of mushrooms ( Cordyceps sinensis, Paecilomyces japonica, Phellinus linteus, Pleurotus ostreatus ) , which exhibited a glucose permeation delay effect at a concentration of 25% or more after 120 minutes , were selected.
이러한 포도당 투과지연 효과는 시료에 함유된 수용성 식이섬유가 점성이 높은 겔을 형성하여 포도당을 포집하기 때문인 것으로 예측되었다.This glucose permeation delay effect was predicted because the water-soluble dietary fiber contained in the sample collected glucose by forming a highly viscous gel.
실시예 1-4: 당부하 정도의 측정 Example 1-4 : Measurement of the degree of sugar load
전기 실시예 1-3에서 선별된 버섯의 혈당조절능력을 생체조건(in vivo)에서 확인하기 위하여, 식이 후의 혈당 농도를 측정하고, 비교하였다.In order to confirm the glycemic control ability of the mushrooms selected in Example 1-3 in vivo, blood glucose levels after diet were measured and compared.
즉, 당뇨를 유발시키는 약물인 스트렙토조토신(streptozotocin)을 생쥐에 체중 kg당 40mg의 양으로 투여하고, 1일이 경과한 후에 혈당치가 250mg/100mL 이상인 쥐들만 선별하였다. 선별된 쥐들을 1일 동안 절식시킨 후에, 말토스 수용액(0.35g/ml) 2ml를 경구투여하고, 실시예 1-3에서 선별된 버섯의 균사체 추출물을 체중 kg당 300mg의 양으로 투여하여 각각의 실험군을 설정하였다. 말토스 용액의 투여 직후, 투여 후 30분, 60분, 90분 또는 120분이 경과된 시점에서 각 실험군으로부터 채혈하고, 채혈된 혈액을 혈당계(Precision Plus Electrodes, Medisense Contract Manufacturing Ltd., UL)에 적용하여, 혈당을 측정하였다(참조: 표 4). 이때, 양성 대조군으로는 펙틴을 동일 양으로 투여한 실험군을 사용하고, 음성 대조군으로는 버섯을 투여하지 않은 실험군을 사용하였다. That is, streptozotocin, a diabetes-causing drug, was administered to the mice in an amount of 40 mg / kg body weight, and after 1 day, only mice having a blood glucose level of 250 mg / 100 mL or more were selected. After fasting the selected mice for 1 day, 2 ml of aqueous maltose solution (0.35 g / ml) was orally administered, and the mycelia extracts of the mushrooms selected in Examples 1-3 were administered in an amount of 300 mg / kg body weight, respectively. The experimental group was set. Immediately after administration of the maltose solution, at 30, 60, 90 or 120 minutes after administration, blood was collected from each experimental group and the blood collected was applied to a blood glucose meter (Precision Plus Electrodes, Medisense Contract Manufacturing Ltd., UL). Blood glucose was measured (see Table 4). In this case, an experimental group in which pectin was administered in the same amount was used as a positive control, and an experimental group in which no mushroom was administered was used as a negative control.
상기 표 4에서 보듯이, 말토스 용액의 투여이후에 혈당이 급격히 증가한 후, 서서히 저하되는 양상을 나타내었으나, 120분이 경과한 이후에는 파에실로마이세스 자포니카(Paecilomyces japonica)를 투여한 실험군만이 혈당이 투여전 보다 저하됨을 알 수 있었다.As shown in Table 4, after the administration of maltose solution, the blood sugar rapidly increased and then gradually decreased, but after 120 minutes, only the experimental group to which Paecilomyces japonica was administered was given blood sugar. It turned out that it is lower than before this administration.
이러한 파에실로마이세스 자포니카의 혈당저하 효과는 α-글루코시다제의 활성억제효과와 시료에 함유된 수용성 식이섬유의 포도당을 포집효과가 서로 상승작용을 일으킨 결과로 분석된다.The hypoglycemic effect of paesillomyces japonica is analyzed as a result of synergistic effect of the inhibitory effect of α-glucosidase and the trapping effect of glucose in the water-soluble dietary fiber contained in the sample.
실시예 2: 버섯배양곡물의 제조 및 효과 Example 2 Preparation and Effect of Mushroom Culture Grains
전기 선별된 파에실로마이세스 자포니카를 이용하여, 버섯배양곡물을 제조하고, 이의 α-글루코시다제의 활성억제효과, 포도당 투과억제 효과, 혈당억제효과를 측정하였다.Mushroom culture grains were prepared using the electroselected Paesylomyces japonica, and the activity inhibitory effect, glucose permeation inhibitory effect, and blood glucose inhibitory effect of α-glucosidase were measured.
실시예 2-1: 버섯배양곡물의 제조 Example 2-1 Preparation of Mushroom Culture Grains
전기 실시예 1-4에서 최종 선별된 파에실로마이세스 자포니카를 배양하여 균사체를 수득하고, 이를 곡물에 접종하여 버섯배양곡물을 제조하였다: 즉, 현미, 보리, 콩, 팥 또는 율무 100g을 15℃의 물에 3시간 동안 침지하고, 수분을 제거한 다음, 121℃, 10기압에서 1시간 동안 살균하고, 파에실로마이세스 자포니카의 균사체를 각각 접종한 후, 28℃로 고정된 배양실에서 3주간 배양하여 각각의 버섯배양곡물을 수득하였다. 이어, 수득한 각각의 버섯배양곡물을 10배 부피의 75%(v/v) 에탄올 수용액으로 3시간씩 2회 반복 추출하였으며, 이를 40℃의 온도에서 감압농축하여 건조시킨 것을 시료로 준비하였다.The final selected Paesylomyces japonica in Example 1-4 was incubated to obtain mycelium, and then inoculated into grains to prepare mushroom culture grains: 100 g of brown rice, barley, soybean, red beans, or even sweet radish at 15 ° C. Immersed in water for 3 hours, water was removed, sterilized for 1 hour at 121 ℃, 10 atm, inoculated with mycelium of Paesilomyses japonica, respectively, and incubated for 3 weeks in a culture room fixed at 28 ℃ Each mushroom culture grain was obtained. Subsequently, the mushroom culture grains thus obtained were repeatedly extracted two times for three hours with a 10-fold volume of 75% (v / v) ethanol aqueous solution, and concentrated to dryness at a temperature of 40 ° C. to prepare a sample.
실시예 2-2: 버섯배양곡물의 α-글루코시다제의 활성억제효과 Example 2-2 Activity Inhibition Effect of α-Glucosidase of Mushroom Culture Grains
전기 실시예 2-1에서 준비된 시료를 사용하여, 실시예 1-2의 방법으로 α-글루코시다제의 활성억제효과를 측정하였다(참조: 표 5). 이때, 대조군으로는 파에실로마이세스 자포니카의 균사체를 배양하지 않은 곡물을 사용하였다.Using the sample prepared in Example 2-1, the activity inhibitory effect of α-glucosidase was measured by the method of Example 1-2 (see Table 5). At this time, the control group was used grains that were not cultured mycelium of Paesilomyses japonica.
상기 표 5에서 보듯이, 버섯배양현미 및 버섯배양보리의 경우에는 α-글루코시다제의 활성억제효과를 나타내었으나, 버섯배양콩, 버섯배양팥 또는 버섯배양율무의 경우에는 α-글루코시다제의 활성억제효과를 거의 나타내지 않았다.As shown in Table 5, in the case of mushroom cultured brown rice and mushroom cultured barley showed the activity inhibitory effect of α-glucosidase, in the case of mushroom culture beans, mushroom cultured red beans or mushroom culture rate of α-glucosidase It showed little activity inhibitory effect.
실시예 2-3: 버섯배양곡물의 포도당 투과지연 효과 Example 2-3 Glucose Permeation Delay Effect of Mushroom Culture Grains
전기 실시예 2-1에서 준비된 각 시료와 1%(w/v) 농도의 포도당을 용해시킨 혼합용액 10mL를 사용하여, 실시예 1-3의 방법으로 포도당 투과지연 효과를 측정하였다(참조: 표 6). 이때, 양성대조군으로는 펙틴을 동일 농도로 사용하고, 음성대조군으로는 파에실로마이세스 자포니카의 균사추출물을 사용하여 비교하였다. The glucose permeation delay effect was measured by the method of Example 1-3 using 10 mL of the mixed solution of each sample prepared in Example 2-1 and glucose of 1% (w / v) concentration (see Table: 6). At this time, pectin was used at the same concentration as the positive control group, and mycelial extract of Paesillomyces japonica was used as the negative control group.
상기 표 6에서 보듯이, 버섯배양현미 및 버섯배양보리의 경우에는 포도당 투과지연 효과가 뚜렷이 나타났으나, 버섯배양콩, 버섯배양팥 또는 버섯배양율무의 경우에는 포도당 투과지연 효과가 거의 나타나지 않음을 알 수 있었다.As shown in Table 6, in the case of mushroom cultured brown rice and mushroom cultured barley, the glucose permeation delay effect was obvious, but in the case of mushroom culture beans, mushroom cultured red beans, or mushroom culture rate, glucose permeation delay effect was hardly observed. Could know.
또한, 대부분의 버섯배양곡물은 전기 선별된 균주의 균사추출물을 사용한 음성 대조군의 경우보다도 우수한 포도당 투과지연 효과를 나타내었으므로, 전기 균주를 곡물에 배양하는 것이 필수적임을 알 수 있었다.In addition, since most mushroom culture grains exhibited a better glucose permeation delay effect than the negative control group using the mycelial extract of the previously selected strains, it was found that culturing the strains in grains was essential.
실시예 2-4: 버섯배양곡물의 당부하 정도의 측정 Example 2-4 : Measurement of sugar load degree of mushroom culture grains
전기 실시예 2-1에서 준비된 각 시료를 사용하여, 실시예 1-4의 방법으로 당부하 정도를 측정하였다(참조: 표 7). 이때, 이때, 양성 대조군으로는 펙틴을 동일 양으로 투여한 실험군을 사용하고, 음성대조군으로는 파에실로마이세스 자포니카의 균사추출물을 동일 양으로 투여한 실험군을 사용하며, 파에실로마이세스 자포니카의 균사체를 배양하지 않은 곡물을 사용하여 비교하였다. Using each sample prepared in Example 2-1, the degree of sugar load was measured by the method of Example 1-4 (see Table 7). At this time, the experimental group administered with the same amount of pectin was used as a positive control group, and the experimental group administered with the same amount of mycelial extract of paesilomyses japonica was used as a negative control group, and the mycelia of paesomyomyces japonica were used. Were compared using uncultivated grains.
상기 표 7에서 보듯이, 버섯배양현미 및 버섯배양보리는 대조군의 현미 및 보리에 비하여 혈당치가 현저히 낮은 수준으로 유지되었으나, 버섯배양콩, 버섯배양팥 및 버섯배양율무는 대조군의 콩, 팥 및 율무와 혈당치가 유사한 수준으로 유지됨을 알 수 있었으므로, 버섯배양현미와 버섯배양보리가 혈당조절효과를 나타냄을 알 수 있었다.As shown in Table 7, the mushroom cultured brown rice and mushroom cultured barley were maintained at a significantly lower blood sugar level than the brown rice and barley of the control, but the mushroom cultured beans, mushroom cultured red beans and mushroom culture rate of the control beans, beans and red beans Since blood glucose levels were maintained at a similar level, mushroom cultured brown rice and mushroom cultured barley showed a glycemic control effect.
또한, 양성 대조군과 음성 대조군에 비하여 대조군의 곡물 및 버섯배양곡물의 혈당치는 높은 수치를 나타내었는데, 이는 곡물에 함유된 당에 기인한 것이다.In addition, the blood sugar level of the grains and mushroom culture grains of the control group showed a high level compared to the positive control group and the negative control group, which is due to the sugar contained in the grains.
이상에서 상세히 설명하고 입증하였듯이, 본 발명은 파에실로마이세스 자포니카를 곡물에 배양하여 제조되고, 혈당조절효과를 나타내는 버섯배양곡물, 전기 버섯배양곡물을 제조하는 방법 및 전기 버섯배양곡물을 주재로 포함하고, 혈당저하 효과를 나타내는 식품을 제공한다. 본 발명의 버섯배양곡물은 포도당의 생성을 저해하고, 생성된 포도당의 체내 유입을 저하시키므로, 혈당조절효과를 나타내는 기능성 식품의 개발에 널리 활용될 수 있을 것이다. As described and demonstrated in detail in the above, the present invention is produced by culturing Paesilomyces japonica in grains, including mushroom culture grains having a blood sugar control effect, a method for producing an electric mushroom culture grains and electric mushroom culture grains as a main To provide a food exhibiting a hypoglycemic effect. Mushroom culture grains of the present invention inhibits the production of glucose, and lowers the influx of the generated glucose in the body, it can be widely used in the development of functional foods exhibiting a glycemic control effect.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020030088211A KR20050054696A (en) | 2003-12-05 | 2003-12-05 | Basidiomycetes-fermented cereal effective in adjusting blood sugar level |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020030088211A KR20050054696A (en) | 2003-12-05 | 2003-12-05 | Basidiomycetes-fermented cereal effective in adjusting blood sugar level |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20050054696A true KR20050054696A (en) | 2005-06-10 |
Family
ID=37249942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020030088211A Ceased KR20050054696A (en) | 2003-12-05 | 2003-12-05 | Basidiomycetes-fermented cereal effective in adjusting blood sugar level |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20050054696A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100936176B1 (en) * | 2008-02-29 | 2010-01-11 | 정영기 | Red Duck Mushrooms (Leatiporussulphureus var. Iiiitus) Extracellular polysaccharides having antidiabetic activity derived from mycelial culture medium and preparation method thereof |
| CN115044477A (en) * | 2021-03-09 | 2022-09-13 | 张清洋 | Isaria japonica strain and application thereof |
| KR20240042299A (en) * | 2022-09-23 | 2024-04-02 | (주)명진푸드시스템 | Composition for lowering blood glucose and method for preparing the same |
-
2003
- 2003-12-05 KR KR1020030088211A patent/KR20050054696A/en not_active Ceased
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100936176B1 (en) * | 2008-02-29 | 2010-01-11 | 정영기 | Red Duck Mushrooms (Leatiporussulphureus var. Iiiitus) Extracellular polysaccharides having antidiabetic activity derived from mycelial culture medium and preparation method thereof |
| CN115044477A (en) * | 2021-03-09 | 2022-09-13 | 张清洋 | Isaria japonica strain and application thereof |
| CN115044477B (en) * | 2021-03-09 | 2023-10-13 | 张清洋 | Isaria japonica strain and application thereof |
| KR20240042299A (en) * | 2022-09-23 | 2024-04-02 | (주)명진푸드시스템 | Composition for lowering blood glucose and method for preparing the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2689951C1 (en) | Mushrooms production method | |
| US10471135B2 (en) | Production of fungal extracellular immune stimulating compounds | |
| US6383799B1 (en) | Process for producing, methods and compositions of glucuronoxylomannan as nutriceutical agent from higher basidiomycetes mushroom | |
| EP1154022B1 (en) | Novel substance originating in basidiomycete culture, process for producing the same and use thereof | |
| EP0753582B1 (en) | Immunopotentiator and method of manufacturing the same | |
| KR101799455B1 (en) | Method for manufacturing the functional drink used the mixing extracts of Inonotus obliquus, Phellinus linteus and Sparassis crispa and its functional drink | |
| JP4602674B2 (en) | Maltase inhibitor | |
| KR100663712B1 (en) | Extracellular polysaccharide with antidiabetic activity obtained from mycelium of situation mushroom and its manufacturing method | |
| JP3284097B2 (en) | Biological antioxidant function enhancer | |
| KR102580526B1 (en) | Method of Preparing Soybean Fermented Mycelium | |
| KR100814351B1 (en) | Physiologically Active Compositions of Basidiomycetes and Araliaaceae | |
| KR20050054696A (en) | Basidiomycetes-fermented cereal effective in adjusting blood sugar level | |
| JP2002087981A (en) | Improving agent for metabolic disorder against sugar and lipid | |
| US6465218B1 (en) | Biologically active substance and process of preparing the same | |
| KR100775133B1 (en) | Method for preparing an antimicrobial or antifungal agent prepared by mixing beta glucan and mushroom mycelium extract, and hand-to-tooth moisturizer containing the agent | |
| KR100534066B1 (en) | Mushroom lactic acid fermented solution including effective ingredients for decreasing the value of blood sugar, and method for manufacturing the solution | |
| JPWO2005077395A1 (en) | Bioactive composition and method for producing the same | |
| JP4647067B2 (en) | Composition derived from basidiomycete culture and use thereof | |
| KR101213069B1 (en) | Inhibitory effects of fermented soymilk on carbohydrate digestive enzymes and postprandial hyperglycemia | |
| CN113303419A (en) | Preparation process of medicinal and edible fungus mixed fermentation mycelium powder | |
| Stamets | Potentiation of cell-mediated host defense using fruitbodies and mycelia of medicinal mushrooms | |
| CN111685234A (en) | Pig feed and method for enhancing immunity by feeding pig feed | |
| JP7453662B2 (en) | Fermented legumes with high dipeptidyl peptidase IV inhibitory activity and method for producing the same | |
| JP7453665B2 (en) | Fermented milk with high dipeptidyl peptidase IV inhibitory activity and method for producing the same | |
| KR20140024549A (en) | Method for manufacturing functional mushroom rice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20031205 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20050630 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20051228 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20050630 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |